LY3127804

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

COVID-19PneumoniaSolid Tumors

Phase 1

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

TerminatedNCT02597036

Eli Lilly and CompanySolid Tumors

Start: 2015-11-06End: 2020-05-24Updated: 2025-10-23

Phase 2

A Study of LY3127804 in Participants With COVID-19

TerminatedNCT04342897

Eli Lilly and CompanyCOVID-19, Pneumonia

Start: 2020-04-20End: 2020-10-12Updated: 2021-08-12

Related Papers

Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine2022-01-018 citations

Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis

Cancer Research2016-07-151 citations